This article is more than 5 years old. Information may no longer be current.
3 vaccines remain in short supply
Click Here to Manage Email Alerts
As a result of the ongoing shortage of the combined diphtheria-tetanus toxoids-acellular pertussis, inactivated poliovirus and Haemophilus influenzae b conjugate and Daptacel vaccines, both manufactured by Sanofi-Pasteur, GlaxoSmithKline has experienced an increased demand for its DTaP-IPV-hepatitis B vaccine, according to a report issued by the CDC.
GlaxoSmithKline is working to meet the increased demand of DTaP-IPV-HepB (Pediarix) but may not be able to keep up with supply during the next 4 to 6 months, until DTaP-IPV/Hib (Pentacel) is available, which is not expected until September.
CDC recommends that providers continue following the recommended immunization schedule. If possible providers should use the same brand and ensure that all patients are vaccinated.
“A child who began the series with Pentacel, then received single-component products at one or more visits may receive Pediarix in lieu of DTaP, IPV, and HepB at subsequent visits when all three vaccines are indicated,” CDC wrote.
CDC recommends providers for Vaccines for Children contact state and local immunization programs for guidelines before ordering vaccines.
For more information:
Disclosure: See the study for a full list of disclosures.